Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Adagio Therapeutics, Inc. (ADGI)

4.64   0.04 (0.87%) 09-13 00:00
Open: 4.62 Pre. Close: 4.6
High: 4.74 Low: 4.4
Volume: 534,999 Market Cap: 506(M)

Technical analysis

as of: 2022-11-18 4:18:23 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 5.53     One year: 6.46
Support: Support1: 3.74    Support2: 3.13
Resistance: Resistance1: 4.73    Resistance2: 5.53
Pivot: 4.59
Moving Average: MA(5): 4.63     MA(20): 4.39
MA(100): 3.97     MA(250): 6.23
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 89.7     %D(3): 90.1
RSI: RSI(14): 70.7
52-week: High: 78.81  Low: 2.41
Average Vol(K): 3-Month: 401 (K)  10-Days: 535 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ADGI ] has closed below upper band by 43.3%. Bollinger Bands are 41.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.74 - 4.77 4.77 - 4.79
Low: 4.35 - 4.37 4.37 - 4.39
Close: 4.6 - 4.64 4.64 - 4.68

Company Description

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Headline News

Thu, 10 Aug 2023

Tue, 28 Feb 2023

Mon, 12 Sep 2022
Adagio Therapeutics Announces Corporate Name Change to Invivyd - Yahoo Finance

Tue, 05 Jul 2022
Mithril Capital's Ajay Royan Sends Letter Thanking Adagio ... - Business Wire

Thu, 06 Jan 2022
U.S. RESEARCH ROUNDUP Akamai Technologies, Gitlab, RPM ... -

Wed, 15 Dec 2021
Top 5 IPOs of 2021 - Investopedia

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 111 (M)
Shares Float 48 (M)
% Held by Insiders 32.5 (%)
% Held by Institutions 67.1 (%)
Shares Short 3,920 (K)
Shares Short P.Month 4,380 (K)

Stock Financials

EPS -14.74
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.69
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) 0
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -220 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.32
PEG Ratio 0
Price to Book value 0.81
Price to Sales 0
Price to Cash Flow -2.35

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.